Pause a failed drug so the tumour becomes sensitive to it again
Resistant cancer cells sometimes come to depend on the very drug they resisted. Stopping the drug for a while can make them vulnerable to it once more.
Drug addiction has been demonstrated for BRAF-inhibitor-resistant melanoma in mice and reported anecdotally in patients rechallenged after a break. Intermittent dosing prevented resistance in those models. A prospective trial would formalise rechallenge: after progression and a defined washout with an intervening therapy, patients are rechallenged with the original agent and monitored with ctDNA for the resistance allele's decline during the holiday.
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
- Tumour heterogeneity and clonal evolution · A tumour is many tumours. Treatments that kill most cells leave the rest to grow back, changed.
Pages like this
not linked directly; found by shared links- IdeaForecast the next resistance mutation like the weather
Shares Drug resistance (primary and acquired), Osimertinib, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy.
- IdeactDNA-guided dose holidays for lung cancer targeted therapy
Shares Osimertinib, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- IdeaSlow the tumour's mutation engine with APOBEC inhibitors during targeted therapy
Shares Osimertinib, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Non-small-cell lung cancer.
- IdeaAutonomous closed-loop adaptive therapy driven by blood tests and evolutionary models
Shares Drug resistance (primary and acquired), Osimertinib, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- IdeaSwitch drugs at maximum response, not at relapse
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Melanoma, Non-small-cell lung cancer.
- IdeaA clone report from blood at every treatment cycle
Shares Osimertinib, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- IdeaTest intermittent dosing of targeted drugs to delay resistance, with honest priors
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy, Melanoma, Non-small-cell lung cancer.
- IdeaFund a biopsy at progression, every time, as standard care
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy, Liquid biopsy (ctDNA).